A5010129592- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- PI3K/AKT/mTOR signaling in cancer
- Lung Cancer Diagnosis and Treatment
- Dermatological and Skeletal Disorders
- Reconstructive Facial Surgery Techniques
- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Colorectal Cancer Treatments and Studies
- Urticaria and Related Conditions
- RNA modifications and cancer
- Health and Medical Research Impacts
- Sarcoma Diagnosis and Treatment
- Global Health and Surgery
- Advances in Oncology and Radiotherapy
- Lymphoma Diagnosis and Treatment
- Tattoo and Body Piercing Complications
- Meningioma and schwannoma management
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Brain Metastases and Treatment
- Genetic and rare skin diseases.
- Nonmelanoma Skin Cancer Studies
- Vascular Tumors and Angiosarcomas
Velindre Cancer Centre
2023-2024
Cardiff University
2016-2024
Velindre NHS Trust
2024
University Hospitals Bristol NHS Foundation Trust
2019
Goethe University Frankfurt
2009
Capivasertib, an AKT inhibitor, added to fulvestrant, was previously reported improve progression-free survival in women with aromatase inhibitor-resistant oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer. The benefit appeared be independent of the phosphoinositide 3-kinase (PI3K)/AKT/phosphatase and tensin homologue (PTEN) pathway alteration status tumours, as ascertained using assays available at time. Here, we report updated overall results, a prespecified...
1005 Background: Previous results from the Phase 2 FAKTION trial (NCT01992952) showed progression free survival (PFS) in patients with aromatase inhibitor (AI) resistant ER+/HER2− advanced breast cancer was significantly longer fulvestrant plus capivasertib vs placebo. At time of analysis, PFS benefit associated not restricted to activating mutations PIK3CA (E542K, E545K, H1047R or H1047L) PTEN protein null. We report now mature overall (OS) data enhanced biomarker analysis. Methods: For...
Several malignant lesions have been reported in association with tattoos, including basal cell carcinomas, squamous carcinomas and melanoma. We report a keratoacanthoma arising recent tattoo. A 60-year-old woman presented tumor on her right leg, over an area of red pigment professional Histological analysis confirmed the clinical diagnosis keratoacanthoma. Although between malignancy tattoos is very uncommon dermatologists dermatologic surgeons should be attentive to this possibility.
<b><i>Introduction:</i></b> Carcinomatous meningitis in breast cancer occurs as a complication up to 5% of all cases. It is very devastating diagnosis, with median patient survival about 3 months. Treatment controversial, and different modalities treatment have been used but none them show significant benefit for overall survival. <b><i>Case Reports:</i></b> We report 2 cases carcinomatous patients. They received similar combination intrathecal...
Key words:follicular mucinosis - mantel cell lymphoma Dacarbazine angiolymphoid hyperplasia with eosinophilia imiquimod lentigo maligna Churg-Strauss syndrome Baboon Barber-Koenigsbeck Cullen gangrene arteiitis temporalis chromhidrosis postmenopausal frontal fibrosing alopecia Langerhans histiocytosis Chilblain lupus erythematosus teleangiectasia macularis eruptive perstans tuberculosis cutis calcinosis Erbium:YAG laser Morbus Heck extramammary Paget’s disease dyskeratosis congenita dimethylfumarate
e14550 Background: Endocrine therapy is the standard of care treatment for patients with estrogen-receptor positive advanced breast cancer, owing to improved tolerability and comparable efficacy that cytotoxic chemotherapy. Half such cancers will progress through first line (primary endocrine resistance) half after an initial period disease control (secondary or acquired resistance). A significant challenge test identify biomarkers which can guide likely success as a single agent in...